Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for over 40 years.
With 90,000+ drug profiles, including 20,000 drugs in active development, it’s the go-to resource for tracking and analyzing the global drug research and development landscape across all disease areas from preclinical to launch.
 |
Access unrivaled historical detail, enabling you to examine R&D trends |
 |
Optimize business development and licensing strategies while identifying new opportunities |
 |
Assess the competitive landscape to identify development threats, gaps, or opportunities, and find fallen angels |
 |
Monitor major market trends such as drug launches, orphan drug status designations, or discontinuations |
Pharmaprojects’ intuitive interface supports fast access to drug development insight for specific diseases, companies, and countries, and can support your strategic decision-making processes.
With our industry-leading platform you can:
You can also access Pharmaprojects via our Drugs API so you can integrate, connect, and deliver multiple sources of information in real-time.
Pharmaprojects also offers seamless integration with Trialtrove and Sitetrove, our clinical trials and site/investigator intelligence solutions.
Penned for the 29th time by Ian Lloyd – Senior Director, Pharmaprojects, the Pharma R&D Annual Review 2021 is ready to transport you into the pharma R&D universe.
This year’s supplement provides detailed statistics, year-on-year trends and insightful analysis on the year’s NAS launches, making this a must-read for the pharma industry.
Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year.
Ian Lloyd – Senior Director, Pharmaprojects, shares his expert insights on the new drugs approved for use in patients that made it to market during the year.
We have received your request and we will get back to you soon.
